TOKYO--(BUSINESS WIRE)--Kyowa Kirin Asia Pacific Pte. Ltd. (President: Chikakuni Kotani, Kyowa Kirin Asia Pacific), a wholly owned subsidiary of Kyowa Hakko Kirin Co., Ltd. (President & COO: Masashi Miyamoto, Kyowa Hakko Kirin), announces it has established an Australian subsidiary, named Kyowa Kirin Australia Pty Ltd (Kyowa Kirin Australia). With the establishment of Kyowa Kirin Australia, Kyowa Kirin Asia Pacific aims to launch Kyowa Hakko Kirin’s global strategic products in the country.
“It is our pleasure to announce we have incorporated our subsidiary in Australia,” said Chikakuni Kotani, President of Kyowa Kirin Asia Pacific. “It was announced last month that Kyowa Kirin Group will be shifting to a new global management structure under the “One Kyowa Kirin” policy. Kyowa Kirin Group will be organized into four regions: North America, EMEA, Asia Pacific and Japan, and business expansion will be accelerated globally. This is Kyowa Kirin Asia Pacific’s first entry into Oceania and we are excited about the future possibilities. We believe Kyowa Kirin Australia will contribute to the health and well-being of patients and families in Australia.”
|
Overview of the Establishment |
||
| Company Name | Kyowa Kirin Australia Pty Ltd | |
| Established | February 27, 2019 | |
| Location | Sydney (planned) | |
| General Manager | To be decided | |
| Paid-in Capital | 5,000,000 AUD | |
| Shareholders | Kyowa Kirin Asia Pacific Pte. Ltd. 100% | |
|
Description of |
Sale of pharmaceutical products in Australia | |
The Kyowa Hakko Kirin Group companies strive to contribute to the health and well-being of people around the world by creating new value through the pursuit of advances in life sciences and technologies.
About Kyowa Kirin
Kyowa Hakko Kirin is a research-based life
sciences company, with special strengths in biotechnologies. In the core
therapeutic areas of oncology, nephrology and immunology/allergy, Kyowa
Hakko Kirin leverages leading-edge biotechnologies centered on antibody
technologies, to continually discover innovative new drugs and to
develop and market those drugs world-wide. In this way, the company is
working to realize its vision of becoming a Japan-based global specialty
pharmaceutical company that contributes to the health and wellbeing of
people around the world.
Kyowa Kirin Asia Pacific is a wholly owned
subsidiary of Kyowa Hakko Kirin, located in Singapore.
You can learn more about the business at: www.kyowa-kirin.com.
